WO2022018779A2 - Composition liquide moussante sûre pour soins personnels - Google Patents

Composition liquide moussante sûre pour soins personnels Download PDF

Info

Publication number
WO2022018779A2
WO2022018779A2 PCT/JO2021/050006 JO2021050006W WO2022018779A2 WO 2022018779 A2 WO2022018779 A2 WO 2022018779A2 JO 2021050006 W JO2021050006 W JO 2021050006W WO 2022018779 A2 WO2022018779 A2 WO 2022018779A2
Authority
WO
WIPO (PCT)
Prior art keywords
acid
foaming composition
fatty acid
composition
present disclosure
Prior art date
Application number
PCT/JO2021/050006
Other languages
English (en)
Other versions
WO2022018779A3 (fr
Inventor
Mayyas Al-Remawi
Original Assignee
University Of Petra
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Petra filed Critical University Of Petra
Publication of WO2022018779A2 publication Critical patent/WO2022018779A2/fr
Publication of WO2022018779A3 publication Critical patent/WO2022018779A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/25—Silicon; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/005—Antimicrobial preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/10—Washing or bathing preparations

Definitions

  • the present disclosure relates to personal care compositions, and more particularly to personal care foaming compositions with natural antiseptic capabilities using alkaline pH 7-10.
  • Ideal personal care products should have cleansing, non-sensitizing and some antiseptic actions to enhance skin, mucosa and hair hygiene with an acceptable safety profile.
  • PCPs Personal care products
  • These groups represent the majority of priority of unrecognized or emerging environment pollutants in everyday urban activities resulting in contaminated sediments and subsequent, far-reaching dispersal into aquatic environments.
  • PCPs contain harmful substances including surface active agents (surfactants), antimicrobials, artificial colors, synthetic fragrance, and solvents, and preservatives.
  • surfactants surface active agents
  • antimicrobials antimicrobials
  • artificial colors artificial colors
  • synthetic fragrance synthetic fragrance
  • solvents and preservatives.
  • Synthetic surfactants are also called detergents are important ingredients in PCPs and can be divided into amphoteric, cationic, anionic surfactants and non-ionic surfactants.
  • the foaming composition may further include an antiseptic agent.
  • the antiseptic agent may be selected from a group including menthol, thymol, or a combination thereof.
  • the amino acid may include 1-arginie.
  • the fatty acid may include a medium chain fatty acid.
  • the fatty acid may be selected from a group including caproic acid or hexanoic acid, caprylic acid or octanoic acid, capric acid or decanoic acid, and lauric acid or dodecanoic acid, or combinations thereof.
  • the fatty acid may include capric acid.
  • the silicate salt may be an alkali earth metal metasilicate.
  • the silicate salt may include sodium metasilicate.
  • the foaming composition may further include one or more excipient acting as a foam stabilizer, and enhancing antimicrobial activity.
  • the one or more excipients may be EDTA, Tris, or a combination thereof.
  • the ratio of the amino acid to the fatty acid may be from about 10 to about 1 by weight.
  • the ratio of the amino acid to the fatty acid may be from about 0.7 to about 1 by weight.
  • the ratio between the silicate salt to the fatty acid may be from about 10 to about 1 by weight.
  • the foaming composition of claim 14, wherein the ratio between the silicate salt to the fatty acid may be from about 0.3 to about 1 by weight.
  • the foaming composition of claim 1, wherein the concentrations of silicate salt, amino acid, and fatty acid may be 0.3, 0.7 and 1 by weight, respectively.
  • FIG. 1 illustrates a column chart comparing foam density (g/ml) of a composition prepared in accordance with embodiments of the present disclosure compared to different anionic and nonionic foaming commercial products available in Jordan.
  • FIG. 2 illustrates a column chart comparing foam density (g/ml) of a composition prepared in accordance with embodiments of the present disclosure upon dilution of with distilled water.
  • FIG. 3 illustrates a comparison showing clarity of a composition prepared in accordance with embodiments of the present disclosure of formula F4 in example
  • FIG. 4 illustrates a comparison showing clarity of a composition prepared in accordance with embodiments of the present disclosure of formula F8 in example 5 (Table 2), wherein 1 represents the composition at room temperature for about 24 hours, and 2 represents the composition in the refrigerator at a temperature from about 4-8 °C for about 48 hours.
  • FIG. 5A illustrates a composition prepared in accordance with embodiments of the present disclosure produced as a foam mass placed on hand.
  • FIG. 5B illustrates a composition prepared in accordance with embodiments of the present disclosure produced as a foam mass placed on hand with gentle rubbing of the foam mass by hands for few seconds.
  • FIG. 5C illustrates disappearance of a composition prepared in accordance with embodiments of the present disclosure produced as a foam mass and placed on hand after gentle rubbing by hands for few seconds.
  • FIG. 6A illustrates a cleansing liquid solution filled in container with foaming pump dispenser showing large amount of foam, the solution prepared in accordance with embodiments of the present disclosure.
  • FIG. 6B illustrates a stable foam formed at a toothbrush head and can be used to clean teeth, the foam formed in accordance with embodiments of the present disclosure.
  • FIG. 7 illustrates a column chart comparing percent viability of dental fibroblast after dilution upon exposure to composition prepared in accordance with embodiments of the present disclosure and commercial mouthwashes available in Jordan.
  • FIG. 8 illustrates a column chart comparing percent viability of dental fibroblast after dilution upon exposure to composition prepared in accordance with embodiments of the present disclosure and commercial toothpastes available in Jordan.
  • FIG. 9 illustrates particle size measured determined as median size diameter of the solution prepared in accordance with embodiments of the present disclosure for hand sanitization (“HS”) and mouthwash (“MW”).
  • HS hand sanitization
  • MW mouthwash
  • FIG. 10 illustrates zeta potential measured for formulations of the solution prepared in accordance with embodiments of the present disclosure for hand sanitization (“HS”) and mouthwash (“MW”).
  • HS hand sanitization
  • MW mouthwash
  • Embodiments of the present disclosure provide environment friendly, biocompatible, natural and safe PCP composition that is free of synthetic surfactants.
  • the composition may include an amino acid, a fatty acid, and a silicate salt.
  • the amino acid may include 1-arginie.
  • the amino acid may include a medium chain fatty acid.
  • the fatty acid may be selected from a group including caproic acid or hexanoic acid, caprylic acid or octanoic acid, capric acid or decanoic acid, and lauric acid or dodecanoic acid, or combinations thereof.
  • the fatty acid may include capric acid.
  • the silicate salt may include an alkali earth metal metasilicate.
  • the silicate salt may include sodium metasilicate.
  • the composition may further include one or more excipient that may act as foam stabilizers, and that may enhance the antimicrobial activity.
  • the one or more excipients may include EDTA, Tris, or a combination thereof.
  • the ratio of the amino acid to the fatty acid may range from about 10 to about 1 by weight.
  • the ratio of the amino acid to the fatty acid may range from about 0.7 to about 1 by weight.
  • the ratio between the silicate salt to the fatty acid is from about 10 to about 1 by weight.
  • the ratio between the silicate salt to the fatty acid is from about 0.3 to about 1 by weight.
  • the concentrations of silicate salt, amino acid, and fatty acid may be 0.3, 0.7 and 1 by weight, respectively.
  • composition in embodiments of the present disclosure may produce a surfactant-free foam using special foam dispenser pump installed on the container closure system.
  • the composition of the present disclosure can be used to produce clear stable liquid with synergistic antiseptic, antimicrobial properties, anti-biofilm formation, anti- malodor, anti-tooth decay.
  • composition of the present disclosure may further include an antiseptic agent.
  • the antiseptic agent may include menthol, thymol, or a combination thereof.
  • the composition can be used as tooth and mouthwash foam with alkaline pH (7 to 9) properties.
  • composition of the present disclosure may be suitable to be on daily basis especially when formulated as mouth wash. Furthermore, the composition can replace toothpastes since it will form stable cleansing and antiseptic foam that can keep oral microbes number under control consequently reducing the tooth decay. Tooth decay usually result from bacteria called streptococcus mutans. In addition, the slight alkaline nature of the composition should preserve the organic content of the tooth enamel.
  • microbes can cause several diseases in the oral cavity such as periodontitis. Oral cavity microbes may create infections that can affect other systems, such as the cardiovascular and renal systems. Even rheumatoid arthritis and pneumonia have been linked to gum diseases. Microbes normally present in the mouth may release toxins that make their way into the brain and it may contribute to Alzheimer’s disease.
  • the composition of the present disclosure may be suitable to be on daily basis as hand sanitizer.
  • the composition is surfactant-free foam producing, alcohol-free safe hand sanitizer. It can reduce the number of microbes on the hands without having a negative impact on human skin or environment on long term use.
  • the composition of the present disclosure can be included in most known in the prior art personal care products in form of solution, spray, liquid soap, solid soap, gel, cream, etc. It can possess suitable emollient and therapeutic power that can give beauty the exhausted or damaged human skin.
  • the purpose is to formulate a liquid alkaline safe foaming composition having cleansing and antiseptic properties.
  • the selected amino acid was arginine and fatty acid was capric acid.
  • the best proportion of arginine and capric acid was determined experimentally. Arginine and capric acid were put in a stirring hot plate and mixed with water while heating up to 40 °C for 10 min. according to Table 1.
  • FIG. 1 A composition containing ( 1 % arginine and 1% capric acid) was compared with 1% of several commercial products.
  • the foaming commercial products were used as surfactant foaming products include Fairy® and Golden ® dish wash, Cameo® hand gel and Loyal® bath gel gels all contain anionic and non-ionic surfactant mixtures.
  • the solutions were placed in container with a standard foaming dispenser. The weight of the foam was determined in a constant volume container. The experiment was repeated three times taking the average and standard deviation. The foam density was calculated in (g/ml) and used for comparison as shown in FIG. 1.
  • Foam density can be used to indicate the amount of liquid required to form a large foam volume filled with air. As the foam density decreases, it indicates that small amount of liquid required to form a fixed foam volume since the volume of the container was constant for all the preparations.
  • the low density foam means smaller solution amount is required to make a large volume of foam which is suitable for hand wash application. Thus, foam will be easily spread on the skin surface and water evaporation rate will be faster.
  • the results of FIG. 1 indicated that suitable low density foam was prepared by formula, (F4) of Example 1, and it was even better than the already known foaming surfactants present in the commercial products available in Jordan.
  • FIG. 2 The purpose is to determine the effect of dilution on foam density.
  • the selected formula of F4 (solution), in Example 1 was exposed to serial dilution to detect the change in foam density upon dilution.
  • the dilution factor was 1, 2, 3, 4, 5 and 6 using distilled water.
  • the density was measured for stable foam at least for 10 seconds. The experiment was repeated three times taking the average and standard deviation. The foam density was calculated and used for comparison as shown in FIG. 2.
  • FIG. 3 The formula (F4) of example 1, was placed in a vial in the refrigerator at temperature (4-8 °C) for 24 h and the appearance was observed visually for its physical clarity. Another vial containing F4 formula was kept at temperature 25 C for 24 h for comparison purposes. Photos for the vials were taken as shown in FIG. 3.
  • FIG. 3 indicated formation of liquid crystals of arginine capric acid compared to clear transparent solution at room temperature.
  • Capric acid is water-insoluble, the addition of arginine enhanced its solubility at room temperature.
  • turbid liquid crystalline state was formed upon cooling down to temperature below 8 C due to decrease solubility in cold conditions.
  • the formula (F4) should be modified by the addition of another additive to keep the materials in solution state even at low temperatures.
  • Any short or medium chain fatty acid (C4-C12) can be used or mixture of fatty acids or fatty acid derivatives or their salts.
  • **Other inorganic and organic antimicrobial active ingredients can be added to enhance biological activity.
  • Tables 3 and 4 showed examples on hand foam preparations that possess cleansing and antispetic effect and can be used in hand sanitizer as shown in FIG. 5.
  • the preparations are physically stable and did not show precipitations at room temperature or in the refrigerator for 48 hours.
  • Tables 5 and 6 indicated examples on mouth/tooth foam preparations with cleansing and antiseptic actions.
  • the preparation can be directly dispensed inside mouth for mouth washing or placed on a tooth brush head and used to clean teeth as shown in FIG. 6.
  • the preparations are physically stable and did not show precipitations at room temperature or in the refrigerator for about 48 hours.
  • Any short or medium chain fatty acid (C4-C12) can be used or mixture of fatty acids or fatty acid derivatives or their salts.
  • Any short or medium chain fatty acid (C4-C12) can be used or mixture of fatty acids or fatty acid derivatives or their salts.
  • MIC minimum inhibitory concentration
  • MMC minimum bactericidal concentration
  • the MIC and MBC of formula in Table 6 in Example 7 was determined using bacterial and fungal microbes i.e Staphylococcus aureus and Candida albican, respectively.
  • the MIC values were assessed using the broth microdilution method by sterile 96- well microtitre plates. Bacterial strains were cultured overnight at 37 °C in Muller Hinton Broth while Sabouraud Broth was used for Candida. Two fold serial dilutions of the formula with medium were prepared in concentration of 100,000 CFU/ml of each microbe. 100 pL of prepared diluted solutions was transferred into 96-well microti tre plates, and then 20 pL of standardized microorganism suspensions was added and incubated at 37 °C for 24 h for the staph and 25 °C for Candida.
  • MBC was determined based on Kirby-Bauer Disc Diffusion. Samples (5 pF) from wells, in which no growth, were cultured in a gar plate and incubated for 24 h at 37 °C. Samples were taken from wells that were considered as MIC and two wells of higher concentration in order to determine MBC for the formula of Staphylococcus aureus and Candida albican. Each experiment was performed in triplicate. All procedures were performed under sterile conditions. In each test, positive and negative controls were used.
  • MIC minimum inhibitory concentration.
  • MBC minimum bactericidal concentration.
  • DF means dilution factor
  • Table 8 summarizes the results of MIC and MBC.
  • DF dilution factor
  • Several commercial mouthwashes MW1, MW2 and MW3 and toothpastes (TB1, TB2 and TB3) were evaluated against formula in Table 6, Example7 with (4-fold concentrated formula).
  • each product was diluted in phosphate buffer saline (PBS) to start with 1 X dilution for our formula and and the 4X dilution with the commercial product.
  • Cytotoxicity was assessed using MTT Thiazoule Blue Tetrazolium Bromide assay.
  • Ninety-six -well microplates were seeded with dental fibroblast cells in complete DMEM at a density of 2X10 4 cells/well. Media was changed every 24h.
  • MW1 composition chlorhexidine. Made in Jordan.
  • MW2 composition aqua, glycerin, propylene glycol, peg-40 hydrogenated castor oil, olaflur, aroma, KC1, chlorhexidine digluconate, aluminum lactate, aspartame, sodium chloride, sodium sulfate,
  • CI42051 patent blue v, (banned in usa ), CI18965 (yellow 2G color E number E107 not listed in UK Food Standards Agency , among EU approved food additives.
  • MW3 composition aqua, alcohol, sorbitol, poloxamer 407, benzoic acid, sodium saccharine, eucalyptol, aroma, methyl salicylate, thymol, menthol, sodium benzoate, ci 42053. Made in Italy.
  • TB1 composition calcium carbonate, aqua, sorbitol, hydrated silica, sodium lauryl sulfate, sodium monofluorophpsphate, aroma, cellulose gum, potssium citrate, trisodium phosphate, sodium saccharine, phenylcarbinol, glycerin, limonene, ci 12490.
  • TB2 composition water, sorbitol, hydrated silica, glycerin, potassium nitrate, cocamidopropyl betaine, flavor, xanthan gum, titanium dioxide, sodium saccharine, sodium hydroxide, sucrose. Made in UK.
  • TB3 composition glycerin, hydrated silica, sodium hexametaphosphate, prpylene glycol, peg-6, aqua, zinc lactate, aroma, sodium gluconate, sodium lauryl sulfate, silica, chondrus crispus powder, sodium saccharin, ci 77891, sodium phosphate, stannous chloride, stannus fluoride xanthan gum, sodium fluoride, cinnamal, ci 74160, limonene. Made in UK.
  • Phosphate buffer 0 1.0 1.0 1.0 1.0 1.0 1.0 Citrate buffer 0 0 0 0.3 0 Acetate buffer 0 0 0 0 0.3 Water qs 100 100 100 100 100 100 100 100 100 100
  • NA No activity.
  • MW3 commercial mouthwash composition aqua, alcohol, sorbitol, poloxamer 407, benzoic acid, sodium saccharine, eucalyptol, aroma, methyl salicylate, thymol, menthol, sodium benzoate, ci 42053. *Selected formula for kill time test.
  • the term “about,” when referring to a value or to an amount of mass, weight, time, volume, concentration or percentage is meant to encompass variations of in some embodiments ⁇ 20%, in some embodiments ⁇ 10%, in some embodiments ⁇ 5%, in some embodiments ⁇ 1%, in some embodiments ⁇ 0.5%, and in some embodiments ⁇ 0.1% from the specified amount, as such variations are appropriate to perform the disclosed method.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Cosmetics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

L'invention concerne une composition moussante pour soins personnels à capacités antiseptiques naturelles ayant un pH alcalin de 7 à 9. La composition peut comprendre un acide aminé, un acide gras et un sel de silicate.
PCT/JO2021/050006 2020-07-19 2021-06-10 Composition liquide moussante sûre pour soins personnels WO2022018779A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063053645P 2020-07-19 2020-07-19
US63/053,645 2020-07-19

Publications (2)

Publication Number Publication Date
WO2022018779A2 true WO2022018779A2 (fr) 2022-01-27
WO2022018779A3 WO2022018779A3 (fr) 2022-05-27

Family

ID=79728561

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JO2021/050006 WO2022018779A2 (fr) 2020-07-19 2021-06-10 Composition liquide moussante sûre pour soins personnels

Country Status (1)

Country Link
WO (1) WO2022018779A2 (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4324396A1 (de) * 1993-07-21 1995-01-26 Henkel Kgaa Reinigungsmittel mit hohem Benetzungsvermögen
WO2013069168A1 (fr) * 2011-11-09 2013-05-16 L'oreal Composition cosmétique pour des fibres kératiniques
US10136645B2 (en) * 2015-02-06 2018-11-27 Microbio Solutions Inc. Antimicrobial composition

Also Published As

Publication number Publication date
WO2022018779A3 (fr) 2022-05-27

Similar Documents

Publication Publication Date Title
DK2433613T3 (en) Non-alcoholic bioactive essential oils mouthwash
RU2648461C2 (ru) Эмульсии для полоскания полости рта
KR102161832B1 (ko) 시스테인과 아연 아미노산 착물
CN109562045B (zh) 口腔护理组合物
CN108289818B (zh) 口腔护理组合物
WO2012018519A1 (fr) Composition de soins buccaux sans alcool ou à faible teneur en alcool et procédé de préparation de ladite composition
JP4591680B2 (ja) 液体口腔用組成物
WO2004028520A1 (fr) Bactericides antiseptiques et cosmetiques, medicaments et produits alimentaires contenant ces bactericides antiseptiques
BRPI0620182A2 (pt) produção de percepção de sabor a partir de óleos essenciais usando um hidrocolóide
JP5359546B2 (ja) 液体口腔用組成物
ES2236752T3 (es) Composiciones antimicrobianas que contienen un alcohol c3-c6.
JP3968131B2 (ja) 抗菌製剤
JP3803695B2 (ja) 抗菌製剤
EP2648681A1 (fr) Composition de soin buccal
WO2019040376A1 (fr) Composé antiseptique topique polymère et procédé d'utilisation
EP3522856B1 (fr) Compositions de soins buccaux
JP2023542023A (ja) プレニル化フラボノイドを含む口腔ケア組成物
CN104606085B (zh) 一种抗菌的醋酸洗必泰纳米乳漱口液及其制备方法
KR101780837B1 (ko) 유화형 액체 구강용 조성물 및 그 제조 방법
JP2011098921A (ja) 口腔用組成物
WO2022018779A2 (fr) Composition liquide moussante sûre pour soins personnels
JP5051347B2 (ja) 液体口腔用組成物
JP2020083787A (ja) 口腔用組成物
WO2002050002A1 (fr) Phenols a substitution phenyle non halogenes, composition antimicrobienne contenant lesdits phenols et procede d'utilisation desdites compositions
JP2006104144A (ja) 歯磨組成物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21846209

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21846209

Country of ref document: EP

Kind code of ref document: A2